Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (10883)	8/17/2018 3:21:47 PM
From: drkaz	Respond to of 12873

I suspect most of us here absolutely believe that the drug candidates work - in that they do effectively bind to, envelope, and dismantle their target viruses quite well. I also suspect that most of us here absolutely believe that the drug candidates are going to be almost completely non-toxic when they do get into full IND-prep toxicity studies. If these drugs now developed work well enough to get FDA approval, we longs are on easy street The problems come back to the same few big questions - that I suspect all of us (or at least most of us) can agree on. 1) When will they ever get scaling up done and completed sufficiently to get into the needed toxicity testing? 2) Assuming they do get scaling up completed - how much dilution are we going to see before that point and how bad is it going to hurt current shareholders? 3) What are the underlying reasons why Dr. Seymour left (forced out or mostly under his own accord)? 4) What are the underlying reasons why Dr. Boniuk resigned his position on the board - the ones stated by him, or the company, or both?